Frekil is the intelligence layer for clinical data. It enables pharmaceutical companies, biotech firms, and CROs to generate Real-World Evidence (RWE) from EHR and claims data in minutes instead of months, with full auditability and regulatory compliance.

Is Frekil HIPAA and GDPR compliant?

Yes, Frekil is fully HIPAA and GDPR compliant, ensuring that all clinical data processing meets the highest standards of data privacy and security required by healthcare regulations.

What industries does Frekil serve?

Frekil is built for pharmaceutical companies, biotech firms, Contract Research Organizations (CROs), and clinical researchers who need to generate Real-World Evidence for regulatory submissions, HEOR studies, and market access.

How does Frekil accelerate clinical evidence generation?

Frekil uses AI-powered automation to handle statistical analysis, propensity score matching, and cohort selection. This reduces the time to generate evidence from 12-18 months to minutes, while maintaining regulatory-grade quality and full auditability.

YBacked by Y Combinator

Intelligence Layer forClinical Data.

Generate Real-World Evidence from EHR & claims data with full auditability. Automate statistical analysis to cut study times from months to minutes.

Built for Pharma, Biotech, CROs & Clinical Researchers

Regulatory-Grade

HIPAA

GDPR

Clinical Workbench

Running Protocol...

Establishing Secure Link...

FREKIL_CLI_V2.4 -- EXECUTION_LOG

Impact Analysis

Cost Savings

$12.4M

60% Reduction vs RCT

Time to Market

-9 Months

Recruitment Skipped

Label Expansion

DETECTED

New Indication Found

Every Day of Delay Costs
More Than Money

Delayed evidence means delayed market access, rejected reimbursement, and lives lost waiting for approval.
Top pharma loses $100M - $1B annually due to inefficient RWE generation.

Manual Workflow

STATUS: MISSED OPPORTUNITIES

Stalled Lifecycle Management

Valuable secondary indications (Label Expansions) remain hidden in data silos.

Weak HEOR Evidence

Delays in Comparative Effectiveness leads to lower reimbursement tiers.

Time to Evidence12-18 Months

Manual WranglingRegulatory & Payer Review

Frekil Intelligence

STATUS: STRATEGIC ADVANTAGE

Accelerated Label Expansion

Proactively identify high-response cohorts for New Indications.

Automated External Control Arms

Simulate control arms using RWE. Save Cost & Time in trials.

Time to EvidenceMinutes

Automated Insight

$300M

Annual Value Unlock

$100M

R&D Cost Savings

18 Mo

Faster Time-to-Market

$383M

Savings per Approval

AI Biostatistician

Frekil isn't just a dashboard; it's a tireless research partner. It understands medical ontologies and statistical methods, automating the heavy lifting.

Automated SAP Generation

Instantly drafts Statistical Analysis Plans aligned with regulatory standards.

Multi-Step Analysis

Executes cohort selection, propensity score matching, and regression modeling.

Publication-Ready Results

Generates tables, graphs (KM curves, Forest plots), and interpreted summaries.

Frekil Agent

Draft an SAP for GLP-1 vs SoC for T2D MACE outcomes.

SAP Draft Generated:

Objective: Compare time-to-MACE.
Population: T2D adults (ICD-10 E11).
Method: Cox Hazards with PSM.

SAP_Draft_v1.pdf

Ready to execute?

Yes, run the analysis.

ANALYSIS COMPLETE

Finding: HR 0.82 (CI 0.74-0.91). Significant.

Commercial Intelligence

Win the
Formulary War

Don't let your drug get stuck in a lower tier. Prove superiority to secure premium reimbursement.

Justify Premium Pricing

Show reduced hospitalizations vs. standard of care.

Sub-Population Dominance

Find cohorts where your drug outperforms by 2x.

Value-Based Agreements

Enter risk-sharing contracts backed by RWE models.

Market Access Probability

94% ↑ 12%

With Frekil RWETier 1

StandardTier 2/3

Insight Unlocked

Competitor shows higher cardiac usage in 65+.

Evidence in minutes,
not months.

Join the forward-thinking biostats teams using Frekil to accelerate their clinical pipeline.

Intelligence Layer forClinical Data.

Every Day of Delay Costs More Than Money

Manual Workflow

Stalled Lifecycle Management

Weak HEOR Evidence

Frekil Intelligence

Accelerated Label Expansion

Automated External Control Arms

AI Biostatistician

Automated SAP Generation

Multi-Step Analysis

Publication-Ready Results

Win the Formulary War

Justify Premium Pricing

Sub-Population Dominance

Value-Based Agreements

Market Access Probability

Evidence in minutes, not months.

Every Day of Delay Costs More Than Money

Manual Workflow

Stalled Lifecycle Management

Weak HEOR Evidence

Frekil Intelligence

Accelerated Label Expansion

Automated External Control Arms

AI Biostatistician

Automated SAP Generation

Multi-Step Analysis

Publication-Ready Results

Win the Formulary War

Justify Premium Pricing

Sub-Population Dominance

Value-Based Agreements

Market Access Probability

Evidence in minutes, not months.

Every Day of Delay Costs
More Than Money

Win the
Formulary War

Evidence in minutes,
not months.

Every Day of Delay Costs
More Than Money

Win the
Formulary War

Evidence in minutes,
not months.